A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...
A wrist-worn, AI-driven transcutaneous peripheral nerve stimulator is linked to greater improvement in patients with ...
Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not ...
To get a more complete account of what took place, The Cavalier Daily reviewed court transcripts and other documents in ...
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System ...
Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ ...
Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...
This valuable study uses EEG and computational modeling to investigate hemispheric oscillatory asymmetries in unilateral spatial neglect. The work benefits from rare patient data and a careful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback